Proactive’s Tylah Tully breaks down Just the Facts of the latest news from Tryptamine Therapeutics Ltd (ASX:TYP, OTC:TYPTF). The company has successfully completed the safety evaluation for its intravenous psilocin formulation, TRP-8803, following a Phase 1b clinical trial. This milestone demonstrates that the treatment was generally safe and well-tolerated, paving the way for further clinical studies. The trial began in June 2024 at CMAX Clinical Research in Adelaide and involved eleven healthy participants who received varying doses of the IV-infused psilocin over a period of up to 150 minutes. The result marks a significant step in Tryptamine's clinical program and will guide the design of upcoming Phase 2 trials. The company plans to build on its earlier success with the oral formulation, TRP-8802, which has shown potential in treating Binge Eating Disorder and Fibromyalgia. The intravenous version, TRP-8803, is expected to provide several advantages over oral psilocybin, such as a faster onset, shorter duration and better control over the therapeutic experience. The next phase will involve additional trials and ongoing regulatory engagement. #ProactiveInvestprs #TryptamineTherapeutics #ASX #JusttheFacts #PsilocybinTherapy #Phase1Trial #TRP8803 #PsilocinFormulation #SafetyEvaluation #BingeEatingDisorder #FibromyalgiaTreatment #PsychedelicTherapy #ClinicalTrials #Pharmacokinetics #PsilocybinResearch #HealthcareInnovation #CMAXResearch #MentalHealth #PsilocybinInfusion #SRCApproval #PsilocybinTherapeutics #TRP8802 #ClinicalDevelopment